IndustryCompany release
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
The nuclear reactor and MOX fuel developer cites a 26% revenue increase, a completed prototype core in Italy and a favourable French regulator opinion on its planned MOX facility.
newcleo (Nasdaq: NWCL), a developer of nuclear reactors and MOX fuel, published preliminary third-quarter 2026 results on 18 November. Product and services revenue was about €10.0M, which the company's headline describes as a 26% increase. Cash stood at €233.4M on 30 September.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): newcleo plc ↗
Article written by VigiEye from the official source (newcleo plc). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026
Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer
🇺🇸 Viatris Inc (VTRS) · Tue 17 Nov 2026